Articles

Lilly falls short on ‘field goal’ attempt

Eli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.

Read More

Lilly grows Alimta’s sales by shrinking market

In 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment
for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales
of the drug have accelerated, growing a whopping 48 percent last year.

Read More

Lilly sues to block copy of Evista osteoporosis drug

Watson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.’s osteoporosis medicine. Indianapolis-based
Lilly is seeking a court order that would block approval until three of its patents expire in 2017.

Read More

Pfizer’s Viagra patent partially rejected in Lilly fight

The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn’t different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.

Read More

Biotech firm plans $28M Greenwood plant

Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.

Read More